Lineage to Present at 2024 BIO International Convention

Lineage to Present at 2024 BIO International Convention

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company's CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tuesday June 4 th , 2024, at 2:30pm in Theater 3. Company representatives are also hosting meetings with potential partners and collaborators to discuss opportunities for strategic alliances across Lineage's novel pipeline of cell therapy transplant programs. The BIO International Convention is the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world, and is taking place June 3-6, 2024, at the San Diego Convention Center in San Diego, CA.

About BIO

BIO is the world's largest advocacy association representing biotechnology companies, academic and research institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. Corporate members range from entrepreneurial companies developing a first product, to Fortune 500 multinationals. BIO also represents state and regional biotech associations, service providers to the industry, and academic centers. Our members help foster a healthy economy by creating good-paying, biotechnology jobs. We also host the largest cost-savings program in the life sciences industry, BIO Business Solutions, which saves nearly $700 million in aggregate for 4,500+ companies every year. For more information visit www.bio.org or follow the organization on X/Twitter @ IAmBiotech .

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or "off-the-shelf," cell therapies to address unmet medical needs. Lineage's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage's neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell .

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
( ir@lineagecell.com )
(442) 287-8963

LifeSci Advisors
Daniel Ferry
( daniel@lifesciadvisors.com )
(617) 430-7576

Russo Partners – Media Relations
Nic Johnson or David Schull
( Nic.johnson@russopartnersllc.com )
( David.schull@russopartnersllc.com )
(212) 845-4242

News Provided by Business Wire via QuoteMedia

LCTX:US
The Conversation (0)
Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

  • Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins
  • Clinical Session Expanded to Include Neuralink
  • Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2 nd Annual Spinal Cord Injury Investor Symposium ("2 nd SCIIS"). The 2 nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advocacy organizations, and the investment community, in order to discuss perspectives on current and future treatment alternatives, impact and support SCI disease awareness and clinical trial participation through the implementation of patient appropriate clinical endpoints, and broaden awareness of and investment of capital into SCI.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

  • Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen ® Program
  • Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit
  • OpRegen Preclinical Results Presented at 2024 Association for Research in Vision and Ophthalmology Annual Meeting
  • OPC1 Clinical Study Start Up Preparation Underway
  • Received CIRM Grant to Support 2 nd Annual SCI Investor Symposium
  • Appointed Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

"The quarter was highlighted by significant milestones and data updates on our lead program," stated Brian M. Culley, Lineage CEO. "A key area of attention for investors is our partnership with Roche and Genentech, and we are pleased to announce a new services agreement which reflects an additional commitment by Genentech for the benefit of the OpRegen program. We believe this agreement will enable our partners to take advantage of our cell transplant expertise to more fully investigate the promising potential of the OpRegen program and do so in a cost-effective manner. We also are planning to bring our second cell transplant program, OPC1, into the clinic this year for a condition with growing awareness of its unmet need and commercial opportunity. Lastly, we continue to build value through the advancement of our early-stage pipeline, which can help create value by capitalizing on the continued validation of our cell transplant approach."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
OpRegen®  Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

OpRegen® Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

  • BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10)
  • BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5)
  • Maintenance or increases in external limiting membrane (ELM) and retinal pigment epithelium (RPE) layers observed by optical coherence tomography (OCT) in patients with extensive bleb coverage of the GA lesion
  • Data suggests OpRegen may counteract RPE cell dysfunction and cell loss in GA by providing support to remaining retinal cells, with effects observed through at least 2 years following a single administration

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month visual acuity results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit . The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute . The presentation, "OpRegen ® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial," was presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update.

Interested parties may access the conference call on May 9 th , 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through May 15 th , 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 1330332.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update.

Interested parties may access the conference call on May 9 th , 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through May 15 th , 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 1330332.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Bold Ventures Announces Prospecting and Sampling Results and Mobilizes Crew to Burchell Gold and Copper Project

Bold Ventures Announces Prospecting and Sampling Results and Mobilizes Crew to Burchell Gold and Copper Project

Bold Ventures Inc. (TSXV: BOL,OTC:BVLDF) (the "Company" or "Bold") is pleased to announce the results of a prospecting and sampling program on its Burchell Gold and Copper Property (the "Property"), located within the Shebandowan Greenstone Belt, approximately 100 km west of Thunder Bay, Ontario. 209 grab samples and 42 channel samples were collected in total. The goal of this phase of work was preparation for a mechanical stripping, sampling and geological mapping program at the 111 Zone gold showing and surroundings. A crew has been mobilized for the mechanical stripping program which will commence immediately.

Highlights from the program include:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Heritage Mining Plans Aggressive Program at Zone 3 Extension Mega-Quartz Vein System at its Flagship Drayton-Black Lake Project

Heritage Mining Plans Aggressive Program at Zone 3 Extension Mega-Quartz Vein System at its Flagship Drayton-Black Lake Project

/ NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Quetzal Copper Announces Refiling of June 30, 2025 Financial Statements

Quetzal Copper Announces Refiling of June 30, 2025 Financial Statements

Quetzal Copper Ltd. (TSXV: Q,OTC:QTZCF) ("Quetzal" or the "Company") announces that it has refiled its interim financial statements and management's discussion and analysis ("MD&A") for the three and six months ended June 30, 2025 (the "Q2 2025 Financial Statements"). The original filings were made on August 28, 2025.

The amendment was made to correct and clarify disclosure relating to the Company's share-based compensation. The Q2 2025 financials originally filed on August 28, 2025 did not reflect the correct number of options and warrants outstanding, and the share-based compensation related to the January 15, 2025 option grant was not accounted for. In this refiling, the correct number of outstanding options and warrants and the share-based compensation related to the January 15, 2025 option grant have now been properly reflected and accounted.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Two Pools Project expands with new tenement applications

Two Pools Project expands with new tenement applications

Corazon Mining (CZN:AU) has announced Two Pools Project expands with new tenement applications

Download the PDF here.

Angkor Resources Receives Approval to Incorporate Mussel Basin into Block VIII Oil and Gas License, Cambodia

Angkor Resources Receives Approval to Incorporate Mussel Basin into Block VIII Oil and Gas License, Cambodia

(TheNewswire)

GRANDE PRAIRIE, ALBERTA (September 10, 2025) TheNewswire - Angkor Resources Corp. (TSXV: ANK,OTC:ANKOF) ("ANGKOR" OR "THE COMPANY") announces its subsidiary, EnerCam Resources Co. Ltd. (Cambodia) ("EnerCam") has received approval from government authorities of Ministry of Mines and Energy for an additional 220 square kilometers added within the Block VIII boundaries, referred to as the Mussel Basin.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×